Rizatriptan Benzoate orally disintegrating tablets are a generic version of Merck's Maxalt MLT Tablets.
Glenmark Pharma 's US generics subsidiary and another generics drugs maker Natco Pharma have received final approval from US Food and Drug Administration for Rizatriptan Benzoate orally disintegrating tablets, used to treat migraine headaches.
Both the companies have approval to sell the tablets in 5mg and 10mg strengths.
Rizatriptan ODT is a generic version of Merck's Maxalt MLT tablets and Glenmark said it will start shipping its tablets immediately.
Natco said it has already started shipping the product launched by its marketing partner Breckenridge Pharmaceuticals.
Rizatriptan ODT had sales of USD 263 million for the year ended March 2013, Glenmark said, citing IMS Health data.
Glenmark now has 87 products authorized for distribution in the US market and 53 ANDAs (abbreviated new drug application) are pending approval with the drug regulator.
Glenmark shares ended up about 1 percent at Rs 575.35 on NSE on Tuesday. Natco ended up 1.5 percent at Rs 454.65.
Glenmark stock price
On August 22, 2014, Glenmark Pharma closed at Rs 719.20, up Rs 6.15, or 0.86 percent. The 52-week high of the share was Rs 749.05 and the 52-week low was Rs 489.10.
The company's trailing 12-month (TTM) EPS was at Rs 15.48 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 46.46. The latest book value of the company is Rs 107.13 per share. At current value, the price-to-book value of the company is 6.71.
READ MORE ON Rizatriptan Benzoate orally disintegrating tablets, ODT, Glenmark Pharma, Glenmark Generics, Merck, Maxalt MLT, tablets, US FDA, Food and Drug Administration, approval, nod, drug regulator
Set email alert for
ADS BY GOOGLE
video of the day
Go for midcaps in cement space, bullish BPCL, IOC: HDFC Sec